Clinical Experience with the MiniMed 670G System in Children, Adolescents, and Young Adults with Type 1 Diabetes

Abstract

Objective: To compare measured HbA1c, estimated HbA1c, and percent time in range before and after the initiation of the Minimed 670G system in children and young adults with type 1 diabetes (T1D). Methods: Data consisted of 67 T1D patients, aged 5-23 years, who started the MiniMed 670G system and were followed for at least 12 weeks. Data were analyzed at baseline and 2, 4, 8, and 12 weeks following Auto Mode start. Paired t tests and linear mixed regression models were used to evaluate the effect of time on percent of time in Auto Mode, percent of time in range (70-180 mg/L) and changes in most recently measured HbA1c and sensor estimated HbA1c. Results: Fifteen percent of patients (n=10) were aged 5-9 years, 27% (n=18) were 10-13 years, 30% (n=20) were 14-17 years and 28% (n=19) were ≥ 18 years; average duration of T1D was 5.47 ± 4.26 years. Nearly 96% of patients were Caucasian; 54% were male. Estimated HbA1c levels decreased from 8.10% ± 1.26% at baseline to 7.51% ± 0.88% at 12 weeks (P<0.0001). Measured HbA1c decreased from 7.98% ± 1.03% to 7.73% ± 1.03% (P=0.0008) (Figure 1). Percent time in range increased from 50% at baseline to 61% at 12 weeks (P<0.0001), without significant change in time below range. Time in Auto Mode declined from 75.1% at start to 68.4% at 12 weeks (P=0.0015). Conclusion: Initiation of the 670G system in a clinical setting led to improved glycemic control in children, adolescents, and young adults. Disclosure C.J. Henson: None. T.L. Barnes: None. A.J. Nickel: None. M. Abuzzahab: Research Support; Self; Ascendis, Genentech, Inc., Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc., Pfizer Inc.. Research Support; Self; Versartis, Inc., Medtronic. Advisory Panel; Self; Sandoz. J. Kyllo: None. L.M. Gandrud: Consultant; Self; UnitedHealth Group.